文献速递肿瘤 PET/CT核素与放射性配体治疗

新型HER2靶向肽探针99mTc-HYNIC-H6F在乳腺癌小鼠模型中的SPECT/CT显像

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models.
PubMed 文献 · J Nucl Med · 2017-01-19

研究制备了靶向HER2的新型SPECT探针99mTc-HYNIC-H6F(标记率大于95%),在HER2阳性MDA-MB-453与HER2阴性MDA-MB-231乳腺癌模型中行小动物SPECT/CT。注射后30分钟MDA-MB-453摄取为每克3.58±0.01%ID,MDA-MB-231为0.73±0.22。结论认为该探针特异性聚集于HER2阳性肿瘤,有望用于HER2阳性肿瘤诊断并监测曲妥珠单抗疗效。

要点

  • 99mTc-HYNIC-H6F标记率大于95%,体外与体内均显示良好的HER2结合特异性。
  • 注射后30分钟MDA-MB-453肿瘤摄取每克3.58±0.01%ID,MDA-MB-231为0.73±0.22。
  • MDA-MB-453摄取可被过量H6F阻断,但不被过量曲妥珠单抗阻断。

核心结论

  • 99mTc-HYNIC-H6F肽探针特异性聚集于HER2阳性肿瘤,有望用于HER2阳性肿瘤的诊断。
  • 由于99mTc-HYNIC-H6F与曲妥珠单抗靶向HER2受体的不同区域,该放射性示踪剂在治疗期间复查HER2表达水平以监测曲妥珠单抗疗效方面也具有很大潜力,且无阻断效应。

研究设计与样本

  • 研究将HER2靶向肽H6F(YLFFVFER)与双功能螯合剂肼基烟酰胺(HYNIC)偶联,制备99mTc-HYNIC-H6F。
  • 在MDA-MB-453(HER2阳性)与MDA-MB-231(HER2阴性)乳腺癌动物模型中使用小动物SPECT/CT研究99mTc-HYNIC-H6F的体内特征。
  • 使用未标记H6F与曲妥珠单抗作为阻断剂,在细胞竞争实验和SPECT显像中研究H6F肽对HER2的特异性及监测曲妥珠单抗治疗的潜在应用。

主要发现

  • 标准tricine/三苯基膦-3,3',3″-三磺酸钠标记流程显示放射化学纯度大于95%。
  • 99mTc-HYNIC-H6F在体外和体内均显示良好的HER2结合特异性。
  • SPECT/CT显像显示MDA-MB-453肿瘤清晰显影,注射后30分钟每克注入剂量百分比为3.58±0.01。
  • HER2阴性MDA-MB-231肿瘤信号远低于MDA-MB-453,注射后30分钟为0.73±0.22。
  • MDA-MB-453的肿瘤摄取可被共注射过量H6F阻断,但不被过量曲妥珠单抗阻断。

临床怎么用

  • 原文结论认为该探针有望用于HER2阳性肿瘤的诊断。
  • 原文结论认为该放射性示踪剂在治疗期间复查HER2表达水平以监测曲妥珠单抗疗效方面具有很大潜力,且无阻断效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overexpression of human epidermal growth factor receptor 2 (HER2) plays important roles in tumorigenesis and tumor progression in breast cancer. Nuclear imaging of HER2 expression in tumors might detect all HER2-positive tumors throughout the body and guide HER2-targeted therapies for patients. We therefore aimed to develop a HER2-targeted peptide probe for breast cancer imaging. A novel SPECT imaging probe, 99mTc-HYNIC-H6F, was prepared and then evaluated in breast cancer animal models. Methods: The HER2-targeted peptide H6F (YLFFVFER) was conjugated with the bifunctional chelator hydrazinonicotinamide (HYNIC). 99mTc-HYNIC-H6F was prepared, and the in vivo characteristics of 99mTc-HYNIC-H6F were investigated in MDA-MB-453 (HER2-positive) and MDA-MB-231 (HER2-negative) models using small-animal SPECT/CT. Moreover, to investigate the specificity of the H6F peptide toward HER2 and the potential applications in monitoring therapies involving trastuzumab, unlabeled H6F and trastuzumab were used as blocking agents in cell competition studies and SPECT imaging. Results: A standard tricine/trisodium triphenylphosphine-3,3',3″-trisulfonate labeling procedure demonstrated that the radiochemical purity was greater than 95%. 99mTc-HYNIC-H6F displayed excellent HER2-binding specificity both in vitro and in vivo. SPECT/CT imaging revealed that the MDA-MB-453 tumors were clearly visualized (percentage injected dose per gram, 3.58 ± 0.01 at 30 min after injection), whereas the signals in HER2-negative MDA-MB-231 tumors were much lower (0.73 ± 0.22 at 30 min after injection). Tumor uptake of MDA-MB-453 was blocked by the coinjection of excess H6F but not by excess trastuzumab. Conclusion: The 99mTc-HYNIC-H6F peptide probe specifically accumulates in HER2-positive tumors and is therefore promising for the diagnosis of HER2-positive cancers. Because 99mTc-HYNIC-H6F and trastuzumab target different regions of the HER2 receptor, this radiotracer also has great potential for monitoring the therapeutic efficacy of trastuzumab by rechecking the expression level of HER2 without blocking effect during therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Li L, Wu Y, Wang Z, et al. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models. J Nucl Med. 2017. PMID: 28104744. doi:10.2967/jnumed.116.183863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。